A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)
This study is testing a new medication called nemtabrutinib to see if it works better than standard treatments for adults with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. These are slow-growing blood cancers that affect white blood cells and lymph nodes.
You might be able to join if you have been diagnosed with active chronic lymphocytic leukemia or small lymphocytic lymphoma that needs treatment for the first time. Participants must also be well enough to carry out daily activities and able to swallow pills easily.
Participants will be randomly assigned to receive either the new study medication, nemtabrutinib, or one of two currently available standard treatments. Your health team will closely monitor you throughout the study to see how well the treatment is working and check for any side effects.
This study is currently recruiting participants at select locations in places like Mobile, Alabama, and Gilbert and Phoenix, Arizona. Your study doctor can give you more details about the exact location closest to you.
- 1Testing a new cancer pill called nemtabrutinib against standard treatments
- 2For adults with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma
- 3Study is currently active and looking for participants
Related videos
2Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.